Paper Details

  1. Home
  2. Paper Details

Ventilatory effects of single, high-dose triazolam in awake human subjects.

Author: BegleR L, BuschM A, SkatrudJ B

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Triazolam, a hypnotic, did not cause respiratory depression in normal subjects at doses two and three times the usual level. However, it altered respiratory cycle timing, increasing breathing frequency.
Paper Details　
Original Abstract of the Article :
The respiratory-depressant effect of the benzodiazepine-derived hypnotic triazolam was investigated with a single oral dose at two and three times the usual dosage in 62 awake normal subjects. A randomized, double-blind protocol compared the following groups: (1) placebo, (2) triazolam, 1.0 mg, (3) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/clpt.1988.212

データ提供：米国国立医学図書館（NLM）

Triazolam: A Hypnotic with Minimal Respiratory Depression in Awake Subjects

Triazolam, a benzodiazepine-derived hypnotic, is commonly used to treat insomnia. However, concerns regarding its potential for respiratory depression have been raised. This study investigates the ventilatory effects of single, high-dose triazolam in awake human subjects. Researchers conducted a randomized, double-blind study involving 62 normal subjects, comparing the effects of placebo, triazolam at two and three times the usual dosage, and morphine.

Triazolam: A Promising Hypnotic with Minimal Respiratory Depression

The study revealed that single doses of triazolam, even at two and three times the usual dosage, did not cause respiratory depression in awake, normal subjects. While triazolam did alter respiratory cycle timing, leading to an increase in breathing frequency, it did not significantly affect minute ventilation, end-tidal PCO2, or the ventilatory response to CO2.

Navigating the Desert of Sleep: A Safe Passage

Think of insomnia as a challenging journey across a vast and endless desert. Triazolam, like a trusted guide, can help individuals navigate this desert and find restful sleep, without compromising their breathing.

Dr. Camel's Conclusion

This study provides reassuring evidence that single, high-dose triazolam does not cause respiratory depression in awake, normal subjects, highlighting its potential as a safe and effective hypnotic option. However, it is crucial to exercise caution and consider individual patient factors, particularly in those with pre-existing respiratory conditions.

Date :
  1. Date Completed 1989-01-24
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

3197367

DOI: Digital Object Identifier

10.1038/clpt.1988.212

Related Literature

Article Analysis
・Effects of triazolam
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.